FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:702-703 February 28, 2002 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Lacroix-Desmazes, S. PubMed Citation

Inhibitory antibodies to factor VIII arise in more than 20 percent of patients with hemophilia A who receive replacement therapy with factor VIII protein.¹ Since these antibodies profoundly complicate the treatment of hemophilia, understanding how they inhibit factor VIII has important clinical implications. In this issue of the Journal, Lacroix-Desmazes and colleagues report the intriguing finding that inhibitory antibodies cause specific proteolytic degradation of factor VIII.² They propose that proteolysis underlies the rapid inactivation of the protein when it is administered to patients who have the antibodies. Confirmation of this proposal could provide new insight into hemophilia and its treatment.

. . . [Full Text of this Article]

References

This article has been cited by other articles:

• Rick, M. E., Walsh, C. E., Key, N. S. (2003). Congenital Bleeding Disorders. ASH Education Book 2003: 559-574 [Abstract] [Full Text]